Z

Zhejiang Shengda Bio-Pharm Co Ltd
SSE:603079

Watchlist Manager
Zhejiang Shengda Bio-Pharm Co Ltd
SSE:603079
Watchlist
Price: 20.24 CNY -0.64% Market Closed
Market Cap: ¥3.8B

Relative Value

The Relative Value of one Zhejiang Shengda Bio-Pharm Co Ltd stock under the Base Case scenario is hidden CNY. Compared to the current market price of 20.24 CNY, Zhejiang Shengda Bio-Pharm Co Ltd is hidden .

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

Zhejiang Shengda Bio-Pharm Co Ltd Relative Value
HIDDEN
Show
Worst Case
Base Case
Best Case

Multiples Across Competitors

Competitors Multiples
Zhejiang Shengda Bio-Pharm Co Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
CN
Zhejiang Shengda Bio-Pharm Co Ltd
SSE:603079
3.8B CNY 4.6 62.6 43.8 43.8
US
Eli Lilly and Co
NYSE:LLY
948.8B USD 16 51.5 34.6 37.1
US
Johnson & Johnson
NYSE:JNJ
563B USD 6 20.9 14.6 17.9
CH
Roche Holding AG
SIX:ROG
286.3B CHF 4.7 30.5 12.9 15
UK
AstraZeneca PLC
LSE:AZN
213.6B GBP 5.1 31.5 15 22
US
Merck & Co Inc
NYSE:MRK
288.1B USD 4.5 15.1 10.7 12.7
CH
Novartis AG
SIX:NOVN
224.1B CHF 5.2 20.3 12.7 16.4
IE
Endo International PLC
LSE:0Y5F
218B USD 94 -74.6 333.1 835.4
DK
Novo Nordisk A/S
CSE:NOVO B
1.4T DKK 4.3 13 9 10.5
US
Pfizer Inc
NYSE:PFE
146.4B USD 2.3 14.9 7.6 10.3
FR
Sanofi SA
PAR:SAN
98.2B EUR 1.7 8.2 7.7 7.7
P/E Multiple
Earnings Growth PEG
CN
Z
Zhejiang Shengda Bio-Pharm Co Ltd
SSE:603079
Average P/E: 26.9
62.6
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
51.5
54%
1
US
Johnson & Johnson
NYSE:JNJ
20.9
6%
3.5
CH
Roche Holding AG
SIX:ROG
30.5
29%
1.1
UK
AstraZeneca PLC
LSE:AZN
31.5
38%
0.8
US
Merck & Co Inc
NYSE:MRK
15.1
14%
1.1
CH
Novartis AG
SIX:NOVN
20.3
17%
1.2
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -74.6 N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
13
2%
6.5
US
Pfizer Inc
NYSE:PFE
14.9
27%
0.6
FR
Sanofi SA
PAR:SAN
8.2
1%
8.2
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
CN
Z
Zhejiang Shengda Bio-Pharm Co Ltd
SSE:603079
Average EV/EBITDA: 45.6
43.8
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
34.6
34%
1
US
Johnson & Johnson
NYSE:JNJ
14.6
2%
7.3
CH
Roche Holding AG
SIX:ROG
12.9
5%
2.6
UK
AstraZeneca PLC
LSE:AZN
15
10%
1.5
US
Merck & Co Inc
NYSE:MRK
10.7
6%
1.8
CH
Novartis AG
SIX:NOVN
12.7
6%
2.1
IE
E
Endo International PLC
LSE:0Y5F
333.1
N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
9
1%
9
US
Pfizer Inc
NYSE:PFE
7.6
0%
N/A
FR
Sanofi SA
PAR:SAN
7.7
8%
1